| Literature DB >> 31700709 |
Amy Gyorkos1, Mark H Baker2, Lauren N Miutz3, Deborah A Lown4, Michael A Jones5, Lori D Houghton-Rahrig6.
Abstract
Introduction One approach to slow the pandemic of obesity and chronic disease is to look to our evolutionary past for clues of the changing behaviors contributing to the emergence of 'diseases of civilization'. Modern humans have deviated from the lifestyle behaviors of our ancestors that have introduced pressures (i.e. diet and activity changes) quicker than our genetic ability to respond. This caused a 'mismatch' between our biological systems and environment, leading to 'man-made' chronic diseases. Purpose The purpose of the study was to investigate the effects of a short-term evolutionarily informed dietary and lifestyle intervention on inflammatory and cardio-metabolic profiles in individuals characterized as having metabolic syndrome (MetS). Methods Twelve subjects with MetS followed a crossover design with two, four-week interventions, including a carbohydrate (CHO)-restricted Paleolithic-based diet (CRPD; <50g CHO) with sedentary activity (CRPD-Sed) and CRPD with high-intensity interval training (CRPD-Ex), separated by a four-week washout period. The HIIT exercise consisted of 10 X 60 seconds (s) cycling intervals interspersed with 60s of active recovery three d/wk for four weeks. The effects of a diet with sedentary activity as compared to a diet with exercise on body composition, as well as the cardiovascular, inflammatory, and metabolic profiles, were assessed. A two-way analysis of variance (ANOVA) with repeated measures was performed with a post-hoc analysis using a simple effects analysis with a Bonferroni adjustment. The level of statistical significance was established a priori as p < 0.05. Results Compared to baselines, CRPD-Sed and CRPD-Ex improved cardio-metabolic markers, including reductions in waist adiposity (-15%, -18%), body mass (-3%, -5%), body fat % (BF%; -7%, -12%), fasting plasma glucose (GLU; -20%, -27%), triglycerides (TG; -47%, -52%), fasting insulin (-34%, -39%), insulin resistance (-35%, -46%), and increased HDL-C (+22%, +36%) and VO2max (+22% and +29%), respectively. CRPD-Sed and CRPD-Ex also reduced inflammatory markers, including hsCRP (-32% and-36%), TNF-alpha (-35% and -41%), IL-6 (-29% and -40%), and ICAM-1 (-19%, -23%), respectively, when compared to baseline. Conclusion Adopting behaviors from our evolutionary past, including diet and exercise, shows favorable cardio-metabolic and inflammatory profiles in those individuals characterized with MetS.Entities:
Keywords: high-intensity interval training; inflammation; insulin sensitivity; ketogenic diet; lipoproteins; metabolic syndrome; metabolism; paleolithic diet; restricted carbohydrate diet
Year: 2019 PMID: 31700709 PMCID: PMC6822889 DOI: 10.7759/cureus.5596
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1The experimental design is a randomized, two-phase crossover trial with a washout period
Twelve subjects characterized by MetS completed both arms of the study, separated by a washout period. Both experimental phases and the washout period lasted four weeks each. Data collection took place at Weeks 0, 4, 8, and 12, which correlated with before and after each phase of the study. N=number of subjects randomized to that respective group; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet without exercise; CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise.
Average nutrient intake for subjects during baseline and diet interventions
Values are mean ± SD; (*) denotes significance between baseline and Week 4 of intervention at p ≤ 0.05; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet with sedentary (without exercise); CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise
| Variable | CRPD-Sed Baseline | Post 4wks | CRPD-Ex Baseline | Post 4 Wks |
| Energy (kcal) | 2189 ± 689 | 1306 ± 539* | 2466 ± 602 | 1590 ± 587* |
| Protein (g) | 82 ± 32 | 71 ± 39 | 80 ± 36 | 87 ± 30 |
| Protein (% energy) | 15 ± 7 | 22 ± 6* | 13 ± 5 | 22 ± 7* |
| Carbohydrate (g) | 268 ± 98 | 52 ± 9* | 277 ± 105 | 51 ± 7* |
| Carbohydrate (% energy) | 49 ± 6 | 16 ± 5* | 45 ± 9 | 13 ± 4* |
| Total Fat (g) | 202 ± 39 | 90 ± 35* | 117 ± 31 | 118 ± 27 |
| Total Fat (% energy) | 37 ± 9 | 62 ± 13* | 43 ± 11 | 67 ± 11* |
| Saturated Fat (g) | 37 ± 12 | 43 ± 17* | 34 ± 11 | 40 ± 14* |
| Monounsaturated Fat (g) | 22 ± 7 | 38 ± 12* | 24 ± 9 | 42 ± 17* |
| Polyunsaturated Fat (g) | 12 ± 4 | 14 ± 6 | 12 ± 6 | 17 ± 9* |
| Alcohol (% energy) | 2 ± 2 | 1 ± 2 | 1 ± 1 | 1 ± 1 |
| Cholesterol (mg) | 443 ± 189 | 654 ± 289* | 398 ± 162 | 687 ± 279* |
Change in body composition following restrictive carbohydrate diet with and without exercise
Values are mean ± SD; *Significance between baseline and week 4 of intervention at p ≤ 0.05; † Significance between CRPD-Sed and CRPD-Ex at p ≤ 0.05; ‡ Significance between CRPD-Sed and CRPD-Ex at p ≤ 0.02 BMI=body mass index; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet with sedentary (without exercise); CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise
| CRPD-Sed | CRPD-Ex | |||
| Variable | Baseline | Post 4 wks | Baseline | Post 4 wks |
| Body Mass (kg) | 97.2 ± 16.7 | 94.1 ± 12.1* | 97.6 ± 15.9 | 92.4 ± 12.2*† |
| BMI (kg/m2) | 35.4 ± 4.3 | 33.2 ± 5.4* | 34.9 ± 6.3 | 30.0 ± 3.4*† |
| Body fat (%) | 42.8 ± 6.4 | 39.6 ± 7.6* | 42.5 ± 5.9 | 37.2 ± 6.2*† |
| Waist Adiposity (cm) | 115 ± 7.4 | 98.0 ± 10.2* | 111.4 ± 5.8 | 91 ± 9.1*‡ |
Change in cardio-metabolic profile following restrictive carbohydrate diet with and without exercise
Values are mean ± SD; *Significance between baseline and Week 4 of intervention at p ≤ 0.05; † Significance between CRPD-Sed and CRPD-Ex at p ≤ 0.05; ‡ Significance between CRPD-Sed and CRPD-Ex at P≤ 0.02 SBP=Systolic Blood Pressure; GLU=Fasting Glucose; HOMA-IR=homeostasis model assessment-insulin resistance; VO2peak=peak aerobic capacity; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet with sedentary (without exercise); CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise
| CRPD-Sed | CRPD-Ex | |||
| Variable | Baseline | Post 4 wks | Baseline | Post 4 wks |
| SBP (mm/Hg) | 130 ± 9.7 | 124 ± 6.6* | 128 ± 9.4 | 122 ± 7.6* |
| GLU (mg/dL) | 114 ± 7.2 | 91 ± 8.4* | 111 ± 10.2 | 81.3 ± 9.1*‡ |
| Fasting Insulin (µUI/ml) | 19.3 ± 9.6 | 12.8 ± 9.1* | 18.2 ± 8.7 | 11.3 ± 9.4* |
| HOMA-IR | 2.6 ± 1.8 | 1.7 ± 0.9* | 2.4 ± 1.1 | 1.3 ± 1.2*† |
| VO2peak(mL·kg-1·min-1) | 23 ± 7.4 | 28 ± 5.5* | 24 ± 8.2 | 31 ± 6.1*† |
Change in lipid profile following restrictive carbohydrate diet with and without exercise
Values are mean ± SD; *Significance between baseline and Week 4 of intervention at p ≤ 0.05; † Significance between CRPD-Sed and CRPD-Ex at p ≤ 0.05; ‡ Significance between CRPD-Sed and CRPD-Ex at p ≤ 0.02 TC=Total Cholesterol; HDL-C=High Density Lipoprotein-Cholesterol; LDL-C=Low-Density Lipoprotein-Cholesterol; TG=Triglyceride; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet with sedentary (without exercise); CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise
| CRPD-Sed | CRPD-Ex | |||
| Variable | Baseline | Post 4 wks | Baseline | Post 4 wks |
| TC (mg/dL) | 222 ± 21.5 | 219 ± 32.1 | 225 ± 26.5 | 209 ± 21.8*‡ |
| HDL-C (mg/dL) | 32 ± 5.2 | 39 ± 7.7* | 33 ± 4.3 | 45 ± 10.1*‡ |
| LDL-C (mg/dL) | 129 ± 23.5 | 135 ± 24.5 | 132 ± 26.9 | 130 ± 21.7 |
| TG (mg/dL) | 216 ± 35.5 | 114 ± 32.9* | 196 ± 31.1 | 94 ± 25.6*‡ |
| TC/HDL-C Ratio | 6.2 ± 1.1 | 2.9 ± 0.7* | 6.0 ± 1.3 | 2.3 ± 0.9*† |
Change in inflammatory profile following restrictive carbohydrate diet with and without exercise
Values are mean ± SD; *Significance between baseline and Week 4 of intervention at p ≤ 0.05; hsCRP=high sensitivity C-reactive protein; TNF-α=tumor necrosis factor-alpha; IL-6=interleukin-6; ICAM-1=intercellular adhesion molecule 1; CRPD-Sed=carbohydrate-restricted Paleolithic-based diet with sedentary (without exercise); CRPD-Ex=carbohydrate-restricted Paleolithic-based diet with exercise
| CRPD-Sed | CRPD-Ex | |||
| Variable | Baseline | Post 4 wks | Baseline | Post 4 wks |
| hsCRP (pg/mL) | 4.1 ± 1.9 | 2.8 ± 1.4* | 3.9 ± 1.7 | 2.5 ± 1.4* |
| TNF-α (pg/ml) | 3.6 ± 1.3 | 2.3 ± 0.6* | 3.2 ± 1.5 | 1.9 ± 0.4* |
| IL-6 (pg/ml) | 3.8 ± 1.2 | 2.7 ± 0.8* | 3.5 ± 0.9 | 2.1 ± 0.6* |
| ICAM-1 (ng/ml) | 296 ± 107 | 239 ± 78* | 289 ± 110 | 223 ± 98* |